NCT02670070

BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone

A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of the Combination of Gemigliptin/Rosuvastatin 50/20 mg in Comparison to Each Component Gemigliptin 50 mg and Rosuvastatin 20 mg Administered in Healthy Male Volunteers

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: LG Life Sciences · Industry
• Sex: Male
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in healthy male volunteers.

Detailed description

This study is to evaluate the safety/tolerability and pharmacokinetics(AUC and Cmax) of the combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in healthy male volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	gemigliptin 50mg, rosuvastatin 20mg	gemigliptin/rosuvastatin 50/20mg

Timeline

• Start date: 2016-03-01
• Primary completion: 2016-04-01
• Completion: 2016-06-01
• First posted: 2016-02-01
• Last updated: 2016-05-11

Locations

1 site across 1 country: South Korea